Dulaglutide as an Add-on to Insulin in Type 2 Diabetes; Clinical Efficacy and Parameters Affecting the Response in Real-World Practice

References

• American Diabetes Association. 9. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes-2019. Diabetes Care . 2019;42(Suppl 1):S90–S102. doi:10.2337/dc19-S009 30559235
   PubMed Web of Science ®Google Scholar
• Yki-Jarvinen H , Kauppinen-Makelin R , Tiikkainen M , et al. Insulin glargine or NPH combined with metformin in type 2 diabetes: the LANMET study. Diabetologia . 2006;49(3):442–451. doi:10.1007/s00125-005-0132-0 16456680
   PubMed Web of Science ®Google Scholar
• Eng C , Kramer CK , Zinman B , Retnakaran R . Glucagon-like peptide-1 receptor agonist and basal insulin combination treatment for the management of type 2 diabetes: a systematic review and meta-analysis. Lancet . 2014;384(9961):2228–2234. doi:10.1016/s0140-6736(14)61335-0 25220191
   PubMed Web of Science ®Google Scholar
• Maiorino MI , Chiodini P , Bellastella G , Capuano A , Esposito K , Giugliano D . Insulin and glucagon-like peptide 1 receptor agonist combination therapy in type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials. Diabetes Care . 2017;40(4):614–624. doi:10.2337/dc16-1957 28325801
   PubMed Web of Science ®Google Scholar
• Diamant M , Nauck MA , Shaginian R , et al. Glucagon-like peptide 1 receptor agonist or bolus insulin with optimized basal insulin in type 2 diabetes. Diabetes Care . 2014;37(10):2763–2773. doi:10.2337/dc14-0876 25011946
   PubMed Web of Science ®Google Scholar
• Jendle J , Grunberger G , Blevins T , Giorgino F , Hietpas RT , Botros FT . Efficacy and safety of dulaglutide in the treatment of type 2 diabetes: a comprehensive review of the dulaglutide clinical data focusing on the AWARD Phase 3 clinical trial program. Diabetes Metab Res Rev . 2016;32(8):776–790. doi:10.1002/dmrr.2810 27102969
   PubMed Web of Science ®Google Scholar
• Blonde L , Jendle J , Gross J , et al. Once-weekly dulaglutide versus bedtime insulin glargine, both in combination with prandial insulin lispro, in patients with type 2 diabetes (AWARD-4): a randomised, open-label, phase 3, non-inferiority study. Lancet . 2015;385(9982):2057–2066. doi:10.1016/s0140-6736(15)60936-9 26009229
   PubMed Web of Science ®Google Scholar
• Tuttle KR , Lakshmanan MC , Rayner B , et al. Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial. Lancet Diabetes Endocrinol . 2018;6(8):605–617. doi:10.1016/s2213-8587(18)30104-9 29910024
   PubMed Web of Science ®Google Scholar
• Pozzilli P , Norwood P , Jodar E , et al. Placebo-controlled, randomized trial of the addition of once-weekly glucagon-like peptide-1 receptor agonist dulaglutide to titrated daily insulin glargine in patients with type 2 diabetes (AWARD-9). Diabetes Obes Metab . 2017;19(7):1024–1031. doi:10.1111/dom.12937 28294499
   PubMed Web of Science ®Google Scholar
• Guja C , Frias JP , Somogyi A , et al. Effect of exenatide QW or placebo, both added to titrated insulin glargine, in uncontrolled type 2 diabetes: the DURATION-7 randomized study. Diabetes Obes Metab . 2018;20(7):1602–1614. doi:10.1111/dom.13266 29473704
   PubMed Web of Science ®Google Scholar
• Rosenstock J , Fonseca VA , Gross JL , et al. Advancing basal insulin replacement in type 2 diabetes inadequately controlled with insulin glargine plus oral agents: a comparison of adding albiglutide, a weekly GLP-1 receptor agonist, versus thrice-daily prandial insulin lispro. Diabetes Care . 2014;37(8):2317–2325. doi:10.2337/dc14-0001 24898300
   PubMed Web of Science ®Google Scholar
• Mathieu C , Rodbard HW , Cariou B , et al. A comparison of adding liraglutide versus a single daily dose of insulin aspart to insulin degludec in subjects with type 2 diabetes (BEGIN: VICTOZA ADD-ON). Diabetes Obes Metab . 2014;16(7):636–644. doi:10.1111/dom.12262 24443830
   PubMed Web of Science ®Google Scholar
• Rodbard HW , Lingvay I , Reed J , et al. Semaglutide added to basal insulin in type 2 diabetes (SUSTAIN 5): a randomized, controlled trial. J Clin Endocrinol Metab . 2018;103(6):2291–2301. doi:10.1210/jc.2018-00070 29688502
   PubMed Web of Science ®Google Scholar
• Stryker MD , Kane MP , Busch RS . A real-world, observational study of weekly exenatide added to basal insulin in patients with type 2 diabetes mellitus (NCT02895672). Endocrinol Diabetes Metab . 2018;1(1):e00004. doi:10.1002/edm2.4 30815541
   PubMedGoogle Scholar
• Pantalone KM , Patel H , Yu M , Fernandez Lando L . Dulaglutide 1.5 mg as an add-on option for patients uncontrolled on insulin: subgroup analysis by age, duration of diabetes and baseline glycated haemoglobin concentration. Diabetes Obes Metab . 2018;20(6):1461–1469. doi:10.1111/dom.13252 29430801
   PubMed Web of Science ®Google Scholar
• Gallwitz B , Dagogo-Jack S , Thieu V , et al. Effect of once-weekly dulaglutide on glycated haemoglobin (HbA1c) and fasting blood glucose in patient subpopulations by gender, duration of diabetes and baseline HbA1c. Diabetes Obes Metab . 2018;20(2):409–418. doi:10.1111/dom.13086 28817231
   PubMed Web of Science ®Google Scholar
• Unni S , Wittbrodt E , Ma J , et al. Comparative effectiveness of once-weekly glucagon-like peptide-1 receptor agonists with regard to 6-month glycaemic control and weight outcomes in patients with type 2 diabetes. Diabetes Obes Metab . 2018;20(2):468–473. doi:10.1111/dom.13107 28862808
   PubMed Web of Science ®Google Scholar
• Kaneko S , Oura T , Matsui A , Shingaki T , Takeuchi M . Efficacy and safety of subgroup analysis stratified by baseline HbA1c in a Japanese phase 3 study of dulaglutide 0.75 mg compared with insulin glargine in patients with type 2 diabetes. Endocr J . 2017;64(12):1165–1172. doi:10.1507/endocrj.EJ17-0189 28904247
   PubMed Web of Science ®Google Scholar
• Yoo JH , Cho YK , Lee J , et al. Clinical efficacy and parameters affecting the response to dulaglutide treatment in patients with type 2 diabetes: a retrospective, real-world data study. Diabetes Ther . 2019;10(4):1453–1463. doi:10.1007/s13300-019-0658-7 31240562
   PubMed Web of Science ®Google Scholar
• Wysham C , Guerci B , D’Alessio D , Jia N , Botros FT . Baseline factors associated with glycaemic response to treatment with once-weekly dulaglutide in patients with type 2 diabetes. Diabetes Obes Metab . 2016;18(11):1138–1142. doi:10.1111/dom.12702 27265893
   PubMed Web of Science ®Google Scholar
• Ahmann A , Rodbard HW , Rosenstock J , et al. Efficacy and safety of liraglutide versus placebo added to basal insulin analogues (with or without metformin) in patients with type 2 diabetes: a randomized, placebo-controlled trial. Diabetes Obes Metab . 2015;17(11):1056–1064. doi:10.1111/dom.12539 26179619
   PubMed Web of Science ®Google Scholar
• Boustani MA , Pittman I , Yu M , Thieu VT , Varnado OJ , Juneja R . Similar efficacy and safety of once-weekly dulaglutide in patients with type 2 diabetes aged ≥65 and <65 years. Diabetes Obes Metab . 2016;18(8):820–828. doi:10.1111/dom.12687 27161178
   PubMed Web of Science ®Google Scholar
• Zhang L , Zhang M , Zhang Y , Tong N . Efficacy and safety of dulaglutide in patients with type 2 diabetes: a meta-analysis and systematic review. Sci Rep . 2016;6:18904. doi:10.1038/srep18904 26742577
   PubMed Web of Science ®Google Scholar
• Htike ZZ , Zaccardi F , Papamargaritis D , Webb DR , Khunti K , Davies MJ . Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: a systematic review and mixed-treatment comparison analysis. Diabetes Obes Metab . 2017;19(4):524–536. doi:10.1111/dom.12849 27981757
   PubMed Web of Science ®Google Scholar
• Mody R , Huang Q , Yu M , et al. Adherence, persistence, glycaemic control and costs among patients with type 2 diabetes initiating dulaglutide compared with liraglutide or exenatide once weekly at 12-month follow-up in a real-world setting in the United States. Diabetes Obes Metab . 2018. doi:10.1111/dom.13603
   Web of Science ®Google Scholar
• Mody R , Grabner M , Yu M , et al. Real-world effectiveness, adherence and persistence among patients with type 2 diabetes mellitus initiating dulaglutide treatment. Curr Med Res Opin . 2018;34(6):995–1003. doi:10.1080/03007995.2017.1421146 29271258
   PubMed Web of Science ®Google Scholar
• Wysham C , Blevins T , Arakaki R , et al. Efficacy and safety of dulaglutide added onto pioglitazone and metformin versus exenatide in type 2 diabetes in a randomized controlled trial (AWARD-1). Diabetes Care . 2014;37(8):2159–2167. doi:10.2337/dc13-2760 24879836
   PubMed Web of Science ®Google Scholar